BridgeBio Oncology Therapeutics (BBOT)
Jennifer Gansert currently serves as the Senior Vice President of Clinical Development at BridgeBio Oncology Therapeutics, where responsibilities include leading the clinical development program strategy for oncology trials focused on RAS-targeting first-in-class agents. Previously, Jennifer held a similar role as Senior Vice President of Clinical Development at BridgeBio from June 2023 to May 2024, and spent 16 years at Amgen as Executive Director. In addition, Jennifer is pursuing graduate studies at Pepperdine Graziadio Business School since August 2021. Educational qualifications include a Doctor of Philosophy in Microbiology and Immunology from UCLA, a Doctor of Medicine from Stony Brook University, and a Bachelor of Arts in Biology from the University of Chicago.
This person is not in any offices
BridgeBio Oncology Therapeutics (BBOT)
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.